Skip to Main Content

Cover Story

December 20, 2010
Volume 88, Number 51
p. 18

Targeting Genes With 'Zinc Fingers'

Stuart A. Borman

© 2010 Sigma-Aldrich
CUTTING TOOL Sigma-Aldrich markets zinc finger nucleases (ZFNs) designed to edit DNA. ZFNs combine zinc fingers (gray, zinc atoms are spheres) that recognize a three-base-pair DNA sequence with a domain (triangle) from the restriction endonuclease FokI, which cleaves DNA (in the red area). The break is then repaired to modify the sequence or create a gene knockout. A, C, G, and T are DNA bases, and C and N are protein termini.
  • Print this article
  • Email the editor

Text Size A A

In 2000, Yen Choo, Chemistry Nobel Laureate Aaron Klug, and coworkers at the MRC Laboratory of Molecular Biology, in Cambridge, England, developed "zinc fingers"—zinc-coordinated protein-based binding agents—that regulate gene transcription by targeting just about any 18-base-pair DNA sequence. The team announced that the technology was being developed by the London-based start-up Gendaq.

Gendaq "did pretty well for itself," says Choo, who is now chief executive officer of the London-based stem cell biotech firm Plasticell. Gendaq made good scientific progress and was sold in 2001 to Sangamo BioSciences for $30 million, Choo notes. Sangamo later licensed research applications of customizable zinc finger technology to Sigma-Aldrich, which now markets it commercially under the trade name CompoZr (C&EN, April 5, page 20).

Researchers now use zinc finger technology to make a variety of genetic modifications—inserting a piece of DNA in a defined place in the genome, creating point mutations in a specific gene, or correcting a gene's sequence defect. "You can knock stuff in, knock stuff out, or change it," Choo says. "Zinc fingers act very specifically to target the particular sequence you're interested in—by virtue of the inherent specificity of zinc fingers and, in particular, of the engineering system that we developed."

Zinc fingers aren't yet being used in any approved therapies, but Choo notes that the opportunities are there for it to happen soon. For example, Sangamo is currently using zinc finger nucleases in three Phase I clinical trials to knock out the gene coding for HIV-entry receptors on patient immune-system stem cells. The idea is to reintroduce the modified cells to the patient in hopes that the cells will form a new population of HIV-resistant immune cells. Sangamo has also completed four Phase II clinical trials of a zinc finger therapeutic in diabetic neuropathy.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2011 American Chemical Society
  • Print this article
  • Email the editor

Services & Tools

ACS Resources

ACS is the leading employment source for recruiting scientific professionals. ACS Careers and C&EN Classifieds provide employers direct access to scientific talent both in print and online. Jobseekers | Employers

» Join ACS

Join more than 161,000 professionals in the chemical sciences world-wide, as a member of the American Chemical Society.
» Join Now!